BioXcel Therapeutics (BTAI) Finished Goods (2022 - 2026)

BioXcel Therapeutics' Finished Goods history runs 5 years deep, the most recent figure standing at $92000.0 for Q1 2026.

• In Q1 2026, Finished Goods fell 48.31% year-over-year to $92000.0; the TTM figure through Mar 2026 stood at $92000.0 (down 48.31% YoY), while the FY2025 annual figure was $37000.0, down 78.61% from the prior year.
• Finished Goods was $92000.0 for Q1 2026 at BioXcel Therapeutics, up from $37000.0 in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $1.4 million in Q2 2024 to a low of $37000.0 in Q4 2025.
• Historically, Finished Goods has averaged $572437.5 across 5 years, with a median of $500000.0 in 2022.
• The sharpest annual moves came in 2023 and 2025: Finished Goods jumped 314.33% in 2023, then plunged 94.97% in 2025.
• A 5-year view of Finished Goods shows it stood at $595000.0 in 2022, then plunged by 31.93% to $405000.0 in 2023, then slumped by 57.28% to $173000.0 in 2024, then sank by 78.61% to $37000.0 in 2025, then soared by 148.65% to $92000.0 in 2026.
• The last three Finished Goods figures came in at $92000.0 (Q1 2026), $37000.0 (Q4 2025), and $65000.0 (Q3 2025), per Business Quant data.